Other OTC - Delayed Quote USD

Clinuvel Pharmaceuticals Limited (CLVLF)

9.66 +0.15 (+1.58%)
As of 1:36 PM EDT. Market Open.
Advanced Chart
Loading Chart for CLVLF
DELL
  • Previous Close 9.51
  • Open 9.66
  • Bid --
  • Ask --
  • Day's Range 9.66 - 9.66
  • 52 Week Range 8.57 - 13.63
  • Volume 100
  • Avg. Volume 338
  • Market Cap (intraday) 484.23M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) 26.11
  • EPS (TTM) 0.37
  • Earnings Date --
  • Forward Dividend & Yield 0.03 (0.34%)
  • Ex-Dividend Date Sep 5, 2023
  • 1y Target Est --

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

www.clinuvel.com

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Clinuvel Pharmaceuticals Limited

Recent News: CLVLF

View More
View More

Performance Overview: CLVLF

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CLVLF
8.17%
S&P/ASX 200 [XJO]
1.22%

1-Year Return

CLVLF
28.87%
S&P/ASX 200 [XJO]
4.82%

3-Year Return

CLVLF
57.77%
S&P/ASX 200 [XJO]
8.82%

5-Year Return

CLVLF
39.97%
S&P/ASX 200 [XJO]
21.59%

Compare To: CLVLF

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

CLVLF
Clinuvel Pharmaceuticals Limited
9.66
+1.58%
Mkt Cap 484.23M
Industry Biotechnology
MSB.AX
Mesoblast Limited
0.9000
+13.21%
Mkt Cap AUD 1.027B
Industry Biotechnology
MESO
Mesoblast Limited
5.88
+6.33%
Mkt Cap 670.737M
Industry Biotechnology

Statistics: CLVLF

View More

Valuation Measures

Annual
As of 4/23/2024

  • Market Cap

    458.98M

  • Enterprise Value

    347.57M

  • Trailing P/E

    25.88

  • Forward P/E

    18.02

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.65

  • Price/Book (mrq)

    4.16

  • Enterprise Value/Revenue

    4.28

  • Enterprise Value/EBITDA

    6.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    36.88%

  • Return on Assets (ttm)

    14.71%

  • Return on Equity (ttm)

    18.98%

  • Revenue (ttm)

    81.76M

  • Net Income Avi to Common (ttm)

    30.15M

  • Diluted EPS (ttm)

    0.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    174.45M

  • Total Debt/Equity (mrq)

    0.60%

  • Levered Free Cash Flow (ttm)

    31.29M

View More

Company Insights: CLVLF

People Also Watch

CLVLY Clinuvel Pharmaceuticals Limited
9.48
+3.16%
 
CMXHF CSL Limited
176.00
0.00%
 
IDRSF Idorsia Ltd
2.1000
0.00%
 
OXBDF Oxford Biomedica plc
2.7200
+3.82%
 
CMVLF Cellectis S.A.
2.6000
0.00%
 
PTCHF PureTech Health plc
2.6400
+1.15%
 
INRLF Valneva SE
3.9000
-2.60%
 
CRPOF Ceapro Inc.
0.1845
0.00%
 
PHGUF Pharming Group N.V.
0.9500
0.00%
 
UCBJY UCB SA
65.20
+0.42%
 
GNMSF Genmab A/S
279.36
-3.56%
 
PRTC PureTech Health plc
26.15
-9.55%
 
MLLCF Molecular Partners AG
3.8000
0.00%
 
FSPKF Fisher & Paykel Healthcare Corporation Limited
16.14
0.00%
 
SBMFF Sino Biopharmaceutical Limited
0.3150
0.00%
 
CHGCY Chugai Pharmaceutical Co., Ltd.
16.75
+0.68%